Advances in Classic and Psychedelic Pharma for Psychiatric Diseases
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Neurobiology".
Deadline for manuscript submissions: closed (20 September 2024) | Viewed by 4021
Special Issue Editor
2. The Leslie and Susan Gonda (Goldschmied) Multidisciplinary Brain Research Center, Bar-Ilan University, Ramat Gan 5290002, Israel
Interests: neuropsychopharmacology; personalised medicine; epigenetics; microbiome
Special Issue Information
Dear Colleagues,
Psychiatric disorders, including post-traumatic stress disorder (PTSD) and depression, are a major public health burden with limited reliable treatments. Current behavioral and pharmacological treatments have limited efficacy; therefore, researchers are looking for novel therapeutic approaches. Interest in psychedelic-assisted treatment in psychotherapy and group treatment vs. individual treatment is growing. This news is especially intriguing since we are shifting from dealing with mood fluctuations to conciseness. As a result, we experience diverse responses to such substances. Findings allude to the molecular mechanisms underlying the idiosyncratic phenomena of psychedelic substances, triggering parallel research of other scientists to create ‘non-psychedelic’ compounds with the same anti-psychiatric effects but without the possible hallucinogenic-like side effects. This Special Issue aims to collect, compare, and discuss these converged findings promptly to reflect the molecular mechanism.
Prof. Dr. Gal Yadid
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- anti-psychiatric drug/treatment
- psychedelic
- molecular mechanism
- neurotransmission
- plasticity
- neurogenesis
- response variability
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
